Outlook Therapeutics, Inc.
OTLK
Rank in Stocks
#19209
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced... Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Share Price
$0.4593
Last synced: 2026-11-09
Market Cap
$111.82M
Change (1 day)
5.25%
Change (1 year)
-64.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Outlook Therapeutics, Inc. (OTLK)
Category
Healthcare
Operating Margin for Outlook Therapeutics, Inc. (OTLK)
Operating Margin as of November 2026 TTM: 4,783.05%
According to Outlook Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 4,783.05%. At the end of 2025 the company had an operating margin of -4,744.25%.
Operating Margin history for Outlook Therapeutics, Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 4,783.05% | -200.82% |
| 2025 | -4,744.25% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -445.61% | -53.58% |
| 2018 | -959.97% | 1.99% |
| 2017 | -941.24% | -45.37% |
| 2016 | -1,723.05% | 93.13% |
| 2015 | -892.18% | 551.65% |
| 2014 | -136.91% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.99% |
US
|
|
| -149.01% | -100.03% |
US
|
|
| 25.57% | -99.99% |
AU
|
|
| 31.23% | -99.99% |
BE
|
|
| 29.35% | -99.99% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Outlook Therapeutics, Inc.'s operating margin
What is Outlook Therapeutics, Inc.'s operating margin?
Outlook Therapeutics, Inc.'s operating margin is 4,783.05%, as of Nov 2026.
What was Outlook Therapeutics, Inc.'s operating margin in 2025?
In 2025, Outlook Therapeutics, Inc.'s operating margin was -4,744.25%, compared with 0.00% in 2024.
How has Outlook Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Outlook Therapeutics, Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-4,744.25%).
How does Outlook Therapeutics, Inc.'s operating margin compare with similar companies?
Outlook Therapeutics, Inc.'s operating margin (4,783.05%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.